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ABSTRACT
Plasmodium falciparum, the organism that causes the most prevalent and most virulent
cases of malaria in humans, poses a major health burden on the developing world, especially in
the tropical regions of Sub-Saharan Africa, Southeast Asia, and Latin America. The burden of
the disease is intensified by the fact that the parasite has developed widespread resistance to all
current antimalarial therapies, such as chloroquine. This drug resistance underscores the need to
develop novel therapeutics that target the parasite, but show low toxicity in the human host.
Protein kinases, because of their integral roles in cell signaling networks, are considered to be
attractive drug targets. Cyclin dependent kinases, or CDKs, and Mitogen-Activated Protein
kinases, or MAPKs, are common to eukaryotes and regulate cellular processes of growth and
proliferation. Plasmodium falciparum Protein Kinase 6, or PfPK6, is an atypical protein kinase
that shows similarities to both MAPKs and CDKs. PfPK6 is expected to have an important role
in the intraerythrocytic cell cycle progression and growth in the malaria organism, as it has been
found to be essential in the parasite.
In order to better understand the function of PfPK6 within Plasmodium, we have
identified serveral potential substrates and interactors of the kinase using coimmunoprecipitation with an HA epitope-tagged cell line of PfPK6, as well as
phosphoproteomic analysis. These methods resulted identification of 15 novel protein
interactors, with 4 being studied for further investigation, and 45 putative substrates after strict
peptide filtering, five of which are used in this study. In order to verify putative substrates and
interactors, both in vitro and in vivo methods were used. In vitro kinase assays using GSTPfPK6 with 5 recombinant substrates confirmed direct phosphorylation of two novel substrates:
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MAL7P1.38, a regulator of chromosome condensation, and PF10_0047, a putative RNA binding
protein. After attempts to generate bacterial constructs of several putative interactors and a
global failure of a usable amount of protein to express under IPTG induction conditions, an
alternative form of expression using a cell free Transcription and Translation reaction (TNT)
with Wheat Germ Extract was used to generate radiolabeled PF11_0154, PFF0625w, and
PF11_0305. Pull down analysis using GST-PfPK6 showed the kinase’s ability to “pull” the
interactors out of solution, confirming the interactions defined by the initial epitope tagged CoImmunoprecipitation. Additionally, for in vivo analysis, parasites were transfected with
RFP- PFF_0695w, an uncharacterized Plasmodium protein, in order to cellular localization of
this interactors. Immunofluorescence assays of transfected lines showed punctate forms of
PFF_0695w in the host erythrocyte in the late trophozoite and schizont stages of the parasite
development, suggesting this interactor is a previously undiscovered protein in the Plasmodium
secretome. The research presented here is an initial step to defining the interactome of PfPK6.
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CHAPTER ONE: INTRODUCTION
1.1: Hypothesis and Specific Objectives

Plasmodium falciparum is the most widespread and virulent cause of malaria in humans,
and places a major burden on the health of the developing world. P. falciparum is a eukaryotic,
single celled protozoan that is transmitted from host to host via the bite of an infected female
Anopheles mosquito, making it very common in tropical regions with high mosquito
populations. It is estimated that upwards of 3.4 billion people are at risk for contracting malaria
each year because of their geographic location. In 2015, there were an estimated 214 million
cases of malaria, 438,000 of which were fatal [1]. The most heavily affect region is Sub-Saharan
Africa, where more than seventy per cent of the cases occur, and many of the cases are in
children under the age of five and pregnant women, who have low immunity to the disease [2].
Although these statistics represent a decrease in incidences from 2000, this decrease can most be
attributed to prevention methods such as distribution of insecticide treated nets, or because of
improved diagnostic methods. However, treatment is becoming more difficult as resistance to
current therapies, such as chloroquine, becomes more widespread. The need to identify novel
drug targets and develop target- specific antimalarial compounds is more pressing than ever.
Protein kinases, because of their integral roles in cell signaling networks, are considered
attractive drug targets. Our lab has identified one such kinase, PfPK6, which shows similarities
to both cyclin dependent kinases (CDKs) and mitogen activated protein kinases (MAPKs) [3].
Both families of kinases are common to eukaryotes and integral to cell cycle regulation [4], and
as such, leads us to suspect that PfPK6 has a similar function to other eukaryotic CDKs and plays
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a role in Plasmodium falciparum cell cycle, growth, and proliferation. This study aims to
elucidate PfPK6’s role in the parasite, which includes determining direct substrates in order to
position the kinase in its phosphorylation cascade, as well as identifying unique protein-protein
interaction complexes that may provide clues to specific function. We hypothesize that
characterization of PfPK6 substrates and interactors will define a preliminary interactome for the
kinase, and will give us a better understanding of PfPK6’s role in signaling networks.
In order to test this hypothesis, we plan to look at two specific groups of interacting
proteins: direct substrates and non-substrate interactors. Substrates of PfPK6 have been
determined using global phosphoproteomics analysis, specifically screening for proline directed
serine/threonine phosphorylation events [5]. The 206 peptides identified were further filtered to
those containing the pS/T-P-X-K/R motif, which is a CDK consensus sequence. PTMScan
Direct® Immunoprecipitation, which identifies post-translational modifications (PTMs), was
used to isolate CDK-like kinase phosphorylation events. The 206 original proteins were
narrowed to 45, and this study has chosen five putative substrates for further investigation.
Potential interactors of PfPK6 were identified in our lab using Co-Immunoprecipitation of
malaria lysates containing an HA epitope-tagged PfPK6. Potential interactors were given
precedence using a unique scoring system based on in order to narrow the list of interactors to
six proteins [6].
With the putative substrates and interactors of PfPK6 identified, we now set out to verify
these interactions both in vitro and in vivo. In vitro kinase assays will determine which potential
substrates are utilized by PfPK6, and the extent to which they are used. Pull down assays using
PfPK6 as bait will confirm protein-protein interactions with purified interactors. Transfection of
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recombinant interactors into malaria cell lines containing GFP tagged PfPK6 will allow us to
verify protein-protein interactions in vivo, to confirm that they are occurring under natural
conditions.
Both substrate and interactor analysis will elucidate PfPK6s role in the intricate signaling
networks of P. falciparum. By examining known functions of these interacting proteins we may
be able to engineer a mechanism of action for this unique kinase. Defining an interactome for
PfPK6 and determining the function of the kinase will put us one step closer to understanding the
unique, multi-stage malarial cell cycle and provide insight into the complex metabolic pathways
of Plasmodium falciparum.

1.2: Literature Review
1.2.1 The Clinical Impact of Plasmodium falciparum

Malaria is one of the most widespread and most harmful diseases in the developing
world. According to the World Health Organization, roughly 3.4 billion people, just shy of half
the world’s population, are at risk for contracting malaria each year. In 2015, there were
between 150 and 300 million recognized cases of malaria, roughly one million of which were
fatal [1]. The causative agents of malaria are one of five species in the genus Plasmodium, of the
Apicomplexan family of unicellular protists. The five human malaria pathogens are P.
falciparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. [7]. Hundreds of species also exist
that infect non-human hosts, including other mammals, reptiles, and birds [8]. Of the five human
malaria species, Plasmodium falciparum causes the most severe forms of malaria and incurs the
highest death rates, with more than 70% of fatalities attributed to falciparum malaria [9].
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Though presentation and symptoms of the disease vary on a case by case basis, P. falciparum
often presents with severe symptoms compared to other strains, including alternating statuses of
fever and rigor, headache, muscle and joint pain, hepato-splenomagaly, severe anemia, and
clotting problems attributed to platelet deficiency [10]. Left untreated, the parasite may also
cause renal failure, seizures, pulmonary edema, and even coma or death [8]. Cases not only pose
a threat to the health of the developing world, but also represent an economic challenge in the
case of hospitalization costs, research costs, and a loss in productivity. Studies indicate that
twelve billion dollars are spent in malaria control and prevention in Sub-Saharan Africa alone,
and that the cost to families is a significant burden, incurring charges for direct medical care
(treatment, diagnosis, medications), incidental charges like transportation, and loss of wages
from the illness [11].
Malaria is transmitted from person to person through the bite of an infected female
Anopheles mosquito. As such, the parasite is endemic to tropical regions that bode well for
mosquito populations, most prevalently Sub Saharan Africa, Southeast Asia, and Central/ South
America. Plasmodium falciparum is hyper-endemic to the African region, and 70% of recorded
P. falciparum cases occurred in this area [12]. Malaria is also endemic to India, Pakistan, and
Indonesia, however, P. vivax infection is more common in this region [12]. Socioeconomic
status also has an effect on the distribution of the disease; areas like the Southern United States
and Mediterranean Europe, who have a climate that could support spread of the parasite, have
largely eliminated endemic infections with public sanitation and with better options for treatment
of the disease [7]. Most cases that occur in developed countries are now brought in by travelers
to malaria infested regions.
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Although malaria still poses a danger to the developing tropics, incidence has decreased
dramatically since 2000. The largest portion of efforts, 25% last year, were directed toward
vector control, such as distribution of insecticide treated bed nets, sanitation of standing water,
and mosquito extermination [13]. The lowest percentage of operational research is conducted on
treatments, likely because of the treatment barriers due to increasingly widespread drug
resistance to traditional therapies like chloroquine, mefloquine, and even artemisinin
combination therapy (ACT). Widespread use of common antimalarial agents has put pressure on
the species to select for drug-resistant strains, with geographic influences and distinct genetic
markers. Chloroquine resistance originated at several focal points, including sites in Africa,
Asia, and Latin America. This has led to alternative therapies such as mefloquine, amodiaquine,
and artemisinin in all regions; resistance to these compounds is developing particularly quickly
in Southeast Asia while non-chloroquine treatments remain effective in Africa [14]. The
genetics of resistance are currently being studied, although it is suspected that point mutations at
multiple loci may be responsible for the resistant phenotype [15]. Single nucleotide
polymorphisms in channels of the malarial digestive vacuole, including PfCRT and PfMDR1, are
implicated in resistance to multiple antimalarial drugs, possibly due to a mechanism of
transportation across the vacuole and detoxification of compounds [16].
Prevention of Plasmodium infections with vaccines is under investigation, however, it is
made difficult by Plasmodium’s numerous mechanisms of evading the host immune system.
Surface antigen expression is regulated by PfEMP1, RIFIN, and STEVOR, which are easily
recognizable non-host proteins expressed on the surface of a parasite-infected RBC [17].
However, the protein not only is able to “rosette” with non-infected RBCs and block antibody
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formation physically [17], it also has a mechanism for fast antigen-determinant switching that
may make it difficult for the host immune system to adapt. There is evidence that the parasite
exhibits site specific recombination at 60 var (variant) sites, much as humans do when
generating antibodies to foreign proteins, and these var sites allow surface expressed proteins to
change quickly during the course of the intraerythrocytic infection, making any host antibodies
generated against antigens obsolete [18]. These considerations make the need for novel drug
compounds even more prevalent.
1.2.2 The Life Cycle of P. falciparum
Plasmodium falciparum and other malaria parasites exhibit a non-canonical cell cycle
that is unique among eukaryotes and includes stages in two different host species (human and
mosquito), in different organ systems, and with both haploid/asexual and diploid/sexual
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components [7]. The figure below is a basic representation of the full malaria cell cycle from
infection by a mosquito vector to transmission to the next host [Figure 1]:

Figure 1: The Life Cycle of the Malaria Parasite
Figure available publicly at http://www.cdc.gov/malaria/about/biology/
During a mosquito blood-feeding on an infected human host, the insect ingests both
macrogametocytes (female), and microgametocytes (male), which, when activated by the drop in
temperature from vertebrate host to mosquito vector and xanthurenic acid produced in the
mosquito midgut [19], begin the process of sexual reproduction. Gametocytes from only one
human host may participate in recombination, therefore genetic diversity in the parasite is
increased when a malaria host was multiply infected with different parent organisms of P.
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falciparum [15]. The zygote resulting from macrogametocyte fertilization develops into a motile
ookinete, which will penetrate the epithelia of the mosquito midgut to reside in the basal lamina
between the midgut and the haemocele. The ookinete has several unique features that aid the
cell in penetrating the mosquito digestive tract, including club shaped micronemes that contain
adhesin and invasin proteins that break down the epithelial cell wall junctions, as well as a
reservoir of “crystalloids,” pigmented proetins in a vacuole used for nutrition and cellular energy
[19]. Once the ookinete settles, it develops into a vegetative oocyst, which undergoes multiple
rounds of nuclear division (without cytokinesis) over ten to fourteen days. The oocyst then
ruptures and releases sporozoites into the mosquito body cavity, which migrate to the salivary
glands to prepare for injection with the next blood meal [19].
Once a malaria parasite has been injected into a human host, it immediately migrates
through the bloodstream into the liver and begins the exo-erythrocytic cell cycle. The invading
cells form parasitous vacuoles within the hepatocytes, and over a period of six to ten days begin
a ten-thousand fold asexual replication, culminating with the release of thousands of merozoites
into the host bloodstream [20]. The liver stages are often asymptomatic in humans, and provide
the parasite protection from the immune system [17]. Plasmodium falciparum usually completes
the liver cycle within six days, while other species of Plasmodium including P. ovale and P.
vivax may remain dormant in the liver by forming hypnozoites, which remain for weeks, months,
even up to a period of thirty years after the initial emergence of infection [7].
The next stage in the cycle is an asexual replication phase that takes place in human
RBCs, known as the intra-erythrocytic cell cycle. This infection stage is responsible for most
malaria symptoms, including anemia due to the parasites feeding on heme, and a characteristic
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cyclic fever over a period of forty-eight hours, the period of the malaria life cycle [11]. There
are four distinct morphologies associated with the blood stages of malaria. The cycle begins
with the ring stage (0-24 hours post infection (HPI)) where the parasite ingests the heme of the
invaded erythrocyte, and the parasite occupies less than a fourth of the cell volume. At this
point, the metabolism is largely anabolic, focusing on generating protein precursors and ATP
molecules through glycolysis for the growing cell [20]. The parasite progresses to trophozoite
stage (~24-36 HPI) once it becomes more irregularly shaped and takes up about half of the
erythrocyte volume. At this point, the parasite rapidly depletes the supply of host hemoglobin
and it is converted into hemozoin crystals which are stored as a reserve in the central vacuole.
The parasite is highly metabolically active, focusing simultaneously on growth and generating
precursors for DNA replication. It is at this stage that the parasite exploits host RBCs transporter
mechanisms and expresses its own proteins on the surface of the erythrocyte [20]. The final two
stages are the schizont and segmenter stages (~36-48 HPI), during which the parasite undergoes
multiple rounds of DNA replication without cytokinesis, generating a large, multinucleated cell
that then ruptures into new merozoites that reenter the bloodstream for reinfection of new RBCs
[21]. Some of the schizonts will differentiate into macro and microgametocytes, which are
accessible for uptake by a new mosquito vector, thus initiating the cycle again.
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The unique cell cycle of organisms in the genus Plasmodium diverges from the normal
paradigm of eukaryotic replication- one cell replicates its DNA and divides into two daughter
cells. Instead of the commonly studied G1, S, G2, M cell cycle progression of most eukaryotes,
Plasmodium exhibits a similar pattern to Drosophila during early embryonic development, which
goes through the first 13 cycles of S-M without cytokinesis. However, P. falciparum still shows
an asynchronicity in DNA replication, so the exact mechanism of schizogeny remains unclear.
Figure 2 shows a representation of the unique cell cycle compared to yeast (normal) and
Drosophila embryo syncytium.
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Figure 2: The Non-Canonical Cell Cycle of Plasmodium
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1.2.3 Cyclin Dependent Kinases and Mitogen Activated Protein Kinases

The subject of this study, PfPK6, shows homology to both cyclin dependent kinases
(CDKs) and Mitogen activated protein kinases, (MAPKs), therefore, we may extrapolate the
function of PfPK6 from the known functions of these two highly conserved families of kinases.
CDKs are common to all eukaryotes, and are ubiquitous regulators of cell cycle progression,
DNA replication, apoptosis, and other growth/differentiation processes [4]. In humans, CDKs
are a particularly intriguing topic in regards to cancer and neurological diseases, because of both
maladies’ root causes in cell cycle checkpoint malfunction. Most CDKs are proline directed and
are phosphorylated at a serine or threonine residue, hidden in the inactive conformation by a
hydrophobic “T-loop.” CDKs must be activated by a cognate cyclin binding partner, and
phosphorylated by a CDK activating complex (CAK) usually CDK7/Cyclin H complex (using
human CDK2 as a model protein) which causes a conformational change in the protein that
moves the T-loop and exposes the active site [22]. This heterodimer active complex is necessary
for downstream phosphorylation in most eukaryotic models. CDKs contain a highly conserved
PSTAIRE motif, which has been used to locate CDK homologues in P. falciparum [6]. PfPK6 is
one of six CDK homologues to be identified in P. falciparum using homology-directed PCR and
database mining, others include PfPK5, Pfmrk, Pfcrk-1, Pfcrk-3, and Pfcrk-4. In addition to
these CDK homologues, four putative cyclins have also been identified, however, the specific
binding partners of these four cyclins remains unclear [6].
Mitogen Activated Protein Kinases are implicated in a three-layer signaling cascade in
eukaryotes. MAPK, MAPKK, and MAPKKK are calcium/calmodulin activated signaling
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kinases that relay extracellular stimuli to the nucleus [23]. This three step process uses the
dynamics of phosphorylation and dephosphorylation to relay messages from outside the cell to
inside the nucleus, regulating complex processes such as growth, cell cycle progression,
morphogenesis, apoptosis, etc, in response to environmental stimuli. PfPK6 has been shown to
localize in the cytoplasm [6], and as such may be a regulator of such a signaling cascade.
1.2.4 Plasmodium falciparum Protein Kinase Six (PFPK6)
Plasmodium falciparum PfPK6, a novel malarial protein kinase, was originally
discovered in our lab using DDRT PCR and was found to show significant homology of both
human CDK2 (57.3%) and MAPK1 (49.6%) [3]. This kinase shows promising similarities to
known eukaryotic CDKs, and as such is postulated to have an integral role in the cell cycle of P.
falciparum. PfPK6 is phosphorylated at Thr14, Thr15, and Thr160, conserved CDK
phosphorylation sites [24]. The kinase has been shown to be sensitive to several known CDK
inhibitors. Previous in vitro kinase assays have shown PfPK6’s ability to autophosphorylate as
well as phosphorylate histone, a DNA binding protein acting as a non-specific substrate [5].
Although it possesses CDK similarity, the traditional PSTAIRE motif is SKCILRE in
PfPK6, and the MAPK phosphorylation residue TXY is replaced by TPT. There is also evidence
to suggest that PfPK6 is acting by a previously unrecognized mechanism as a “cyclinindependent kinase.” Not only has PfPK6’s activating cyclin not been identified, but the same
kinase assays mentioned above did not take place in the presence of any known cyclin, showing
that PfPK6 is fully active as a monomer [25]. Additionally, presence of known eukaryotic
cyclins has not been shown to stimulate PfPK6 in any in vitro or in vivo studies [3].
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1.2.5: Significance of PfPK6 Substrate and Interactor Identification/Characterization
PfPK6 is a vital kinase to the life cycle of Plasmodium falciparum, as shown by previous
knockdown assays supplemented with plasmid containing the gene for PfPK6 [24]. Therefore, if
this kinase is essential to the intraerythrocytic growth of the parasite, inhibition would effectively
kill the organism, as is the goal with anti-malarial drugs. Many drugs that are current kinase
inhibitors target the catalytic ATP binding pocket; this sequence is highly conserved among
eukaryotes, so traditional kinase inhibitors are bound to show toxicity to the human host.
Therefore, it is important to determine PfPK6’s unique substrates, interacting partners, and
positive/negative regulators, because upstream inhibition of these proteins (with little homology
to human proteins) would generate a Plasmodium-specific inhibitor with low host specificity.
Identifying novel substrates and interactors would also reveal unique binding sites other than the
catalytic pocket that could be targeted. Figure 3 summarizes the significance of this project and
its long term goals.
PfPK6:
Potential
Drug Target

•Vital to P. Falciparum
function
•In silico identification of conserved CDK
recognition Sequences
HA-Epitope Tagged CoImmunoprecipitation

Identify
Substrates
and
Interactors

Identification
of
Biochemical
Pathways

•

Understanding of the P. falciparum
unique cell cycle

Drug Target:
Regulator of
PfPK6
High
Throughput
Screening/
Drug Discovery

Figure 3: Significance of PfPK6 Substrates and Interactors
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1.3: Identification of PfPK6 Substrates and Interactors
1.3.1 Global Phosphoproteomics Analysis Reveals CDK-like Substrates
Plasmodium falciparum digresses in its cyclical progression from the paradigm of other
eukaryotic cell cycles; while most organisms go through a cycle of growth, one DNA replication,
and cytokinesis into two daughter cells, P. falciparum has a non-canonical cycle of multiple
rounds of nucleic acid replication without cytokinesis followed by rupture into multiple new
merozoites. The six unique CDK-related kinases discovered in the parasite are likely to be
regulators of this unique life cycle. In order to further elucidate the function of PfPK6, it is
important to examine the substrates that are directly phosphorylated by the kinase. Previous
global phosphoproteomics analysis generated a dataset that could be used to examine potential
substrates based on the presence of certain motifs [5]. PfPK6 is a proline directed
serine/threonine kinase, so analysis of this motif resulted in the identificiation of 206 unique
peptides. These were further narrowed to proteins containing the strong CDK consensus
sequence pS/T-P-X-K/R, resulting in 45 putative substrates of the six CDK-like kinases. To
supplement this dataset, PTMScan® Direct immunoprecipitation was performed to identify posttranslational modifications, in this case serine/threonine phosphorylation at the strong CDK
sequence. Using phospho-motif antibodies, 48 additional unique phosphorylation events were
identified [5].
Four of the putative substrates were chosen for further analysis based on the workability
of the gene of interest and the predicted function of the peptide. One of the chosen proteins,
PFE-155w is a homologue of the origin recognition complex, which are components of the pre-
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replication complex and present a checkpoint in other eukaryotes that prevents re-replication of
DNA at G1. One putative substrate was identified by both methods of analysis; MAL7P1.38 is a
suspected regulator of chromosome condensation. PF10_0047 is a putative RNA binding
protein. It is crucial to identify which of these proteins PfPK6 may act on in the parasite in order
to understand its network of interaction and ultimately its role in the organism. Figure 4 shows
identification of pS/T-P-X-K/R phosphorylation at different cell stages [5] and Figure 5 shows a
table of putative kinases and their predicted functions.

Figure 4: Phosphoproteomics analysis of Strong CDK consensus sequence
Figure from Pease et. Al Global analysis of protein expression and phosphorylation of three
stages of Plasmodium falciparum intraerythrocytic development [5].
Gene ID
MAL7P1.38

Putative Function
Regulator of Chromosome Condensation

PF10_0047
PF11_0332
PFE0155w

RNA Binding Protein
Uncharacterized Plasmodium Protein
Orc1/CDK6 Homologue

Figure 5: Putative PfPK6 Substrate and Predicted Function
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1.3.2 Co-Immunoprecipitation of P.Falciparum Lysates Reveals a Potential PfPK6
Interactome
Although substrate analysis is vital to the understanding of any protein kinase, PfPK6
also must have positive and negative regulators and other non-substrate binding partners within
the cell in order to contribute to the unique signaling pathways of Plasmodium falciparum. In
order to generate an understanding of the interactome, an HA-tagged PfPK6 cell line was
subjected to Anti-HA Co-immunoprecipitation. The HA lines were generated by replacing
normal loci flanking the kinase with the tag via homologous recombination, and the presence
was verified using Western blotting [6]. The Anti-HA antibodies, cross-linked to agarose beads,
were expected to pull out the kinase, which would in turn pull the interacting partners out of
solution. Following mass spectrometry analysis of the wild type and HA-PfPK6 cell line eluent,
this technique identified 15 unique interacting partners that were not shown to interact with two
of the other CDK kinases, PfPK5 or Pfmrk. These fifteen interactors were scored using a ratio of
presence in the wild type to presence in the experimental line so as to eliminate non-specific
interactions and generate the “top hits” for further investigation [6]. Images for the Coimmunoprecipitation as well as unique interactors and their putative functions can be seen below
in Figures 6 and 7.
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Figure 6: Co-Immunoprecipitation of 3D7 Wild Type and HA-PfPK6

Figure depicts a silver stained gel of 3D7 wild-type Anti-HA CoIP (left) and HA- PfPK6 cell line
(right). Figure from Pease, Proteomic analysis delineates the signaling networks of Plasmodium
falciparum.
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Figure 7: Identifying the PfPK6 Interactome: Putative Interactors and Predicted Function
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CHAPTER TWO: CHARACTERIZATION AND VERIFICATION OF
SUBSTRATES AND INTERACTORS OF PfPK6
2.1: Materials and Methods
Understanding and verifying both the substrates and interactors of PfPK6 is essential to
delineating the function of the kinase within the organism. The following methods will allow us
to confirm the identified substrates and interactors both in vitro and in vivo, which will supply
insight into PfPK6’s unique biochemical pathways and ultimately put us closer to understanding
its unique role in the malarial cell cycle.

2.1.1 Cloning and Expression of Recombinant PfPK6 and Putative Substrates and Interactors
In order to elucidate the role of PfPK6 in relation to its respective substrates and
interactors, recombinant forms of both the kinase and other proteins were generated. PfPK6 was
cloned into a pGEX6P1 vector with an N-terminal GST tag. Putative substrates, MAL7P1.38,
PFE0155w, PF11_0332, PF10_0047, and PFC0805w, as well as three potential interactors,
PF11_0154, PFF0625W, and PF11_0305 were amplified from P. falciparum cDNA using PCR
and cloned into pET30 EK/LIC (Novagen) vectors containing a 6x histidine tag at the Cterminus. Inserts were confirmed via Sanger sequencing to ensure correct base pair sequence
and open reading frames prior to use. Verified clones were transformed into BL21 (DE3) (RIPL)
competent cells (Strategene) and used to inoculate a 5mL culture of Miller Luria broth, which
was grown overnight at 37°C. The 5mL starter culture was then used to inoculate 500mL LB
and the culture was grown to log growth phase as measured by spectrophotometer OD 600 (0.40.6 absorbance). The cells were induced with 0.1mM (PfPK6 and putative substrates) or 1.0mM
(interactors), and were grown for ~14 hours at 20°C and ~12 hours at 30°C respectively.
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2.1.2 Purification of Recombinant PfPK6
Induced cultures containing GST-PfPK6 were harvested by centrifugation at 10,000 rpm
for 10 minutes at 4°C. The supernatant was removed and the bacterial pellet was resuspended in
20mL of 300 mM MK binding buffer containing 40mM Hepes (pH 7.4), 300mM NaCl, 0.02%
monothioglycerol with the addition of 100µL of 100x HALT protease inhibitor (ThermoFisher).
Cell lysis was initiated by adding 1 mg/mL lysozyme and incubating for 30 minutes on ice with
periodic inversion every 5 minutes. The sample was then sonicated for ~40 cycles of 30 seconds
power/30 seconds rest on ice until 80% lysis was achieved as monitored by spectrophotometer
OD600 readings. The lysate was cleared by centrifugation at 30,000 rpm for 30 minutes at 4°C
in an ultracentrifuge. The supernatant was filtered using Whatman syringe filtration to ensure
the sample was clear. The supernatant was then aspirated and injected into AKTA FPLC
machine with a 1mL GSTrap® column for purification (General Electric). The column was
eluted using MK buffer containing 40mM HEPES (pH 7.4), 200mM NaCl, and 20mM reduced
glutathione. Fractions were collected and a 10µL aliquot was analyzed using SDS-PAGE to
ensure sample purity. The fractions containing pure PfPK6 were pooled and dialyzed overnight
with buffer changes every 2 hours against TBS using the Slide-a-Lyzer® 10,000 MW cassette
(ThermoFisher). The dialyzed sample was concentrated using Vivaspin 2® 10,000 MWCO spin
columns (Sartorius) and concentration was assessed using a standard Bradford concentration
assay.
2.1.3 Purification of Putative Substrates and Interactors
Induced cultures containing His-tagged substrates and interactors were harvested by
centrifugation at 10,000 rpm for 10 minutes at 4°C. The supernatant was removed and the
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bacterial pellet was resuspended in 20mL His-Link Binding Buffer containing 100 mM Hepes
pH 7.5, 10 mM Imidazole, 300 mM NaCl with the addition of 100µL of 100x HALT protease
inhibitor (ThermoFisher). Cell lysis was initiated by adding 1 mg/mL lysozyme and incubating
for 30 minutes on ice with periodic inversion every 5 minutes. The sample was then sonicated
for ~40 cycles of 30 seconds power/30 seconds rest on ice until 80% lysis was achieved as
monitored by spectrophotometer OD600 readings. Lysate was cleared by centrifugation at
20,000 rpm for 30 minutes at 4°C and supernatant was decanted. 3mL of His-Link resin (50%
slurry) (Promega) was added to the supernatant and incubated overnight at 4°C with gentle
rocking. The following morning, the resin was washed and added to a gravity flow column for
elution with 100 mM Hepes (pH 7.5) and 250 mM Imidazole. 20µL aliquots were taken and
analyzed using SDS-PAGE for assessment of protein purity. Pure fractions were pooled and
concentrated using Vivaspin 2® 10,000 MWCO spin columns (Sartorius) and concentration was
determined using Bradford assay.
2.1.4 Western Blot Analysis of PfPK6 Interactors
Because of poor expression and purification results of interactors PF11_0154,
PFF0625w, and PF11_0305, Western Blot analysis was performed to verify that the proteins
were being expressed without expected overexpression. Cultures were grown up and induced as
described previously, and 1mL of a control non-induced culture and 1 mL of induced culture was
harvested for analysis. Samples were pelleted by centrifugation at 13,000 rcf x g for 1 minute
and supernatant was removed. The pellets were resuspended in 100µL of 1x gel loading buffer
containing SDS and boiled for 10 minutes. 10µL of sample was loaded onto a 12% SDS-PAGE
and run at 100V for ~1.5 hours, until the blue dye front reached the bottom of the cassette. The
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gel was then transferred onto a PVDF membrane using the NuPAGE wet transfer module with
1X NuPAGE Transfer buffer (Invitrogen) at 30V for 1 hour at 4°C. Following transfer, the
membrane was blocked overnight using 5% milk in tris-buffered saline containing 0.1% Tween
20 (TBS-T). The following morning, fresh blocking solution was applied with the addition of a
1:3000 dilution of Mouse-anti-His antibodies, and incubated for 2 hours at room temperature on
a Belly-dancer rotating platform. The membrane was then washed three times in blocking
solution for 10 minutes at room temperature with rotation. Fresh blocking solution was added
with the addition of a 1:5000 dilution of Goat-anti-Mouse HRP conjugated secondary antibody
and incubated for 2 hours at room temperature on the Belly Dancer. The membrane was washed
with TBS-T and developed using enhanced Chemiluminescence detection (BioCell Sciences).
2.1.5 In vitro Kinase Assays
Kinase assays were performed using GST-PfPK6 in order to test the kinase’s ability to
directly phosphorylate any of the putative substrates. 1µg of PfPK6 and 5µg of each substrate
was used and brought to a total volume of 30µL using a standard kinase buffer containing 20mM
Tris/HCl (pH 7.5), 20mM MgCl2, 2mM MnCl2, 10μM ATP, and 5μCi (γ-32P) as described by
Dorin, D. et. al [26]. The reactions were incubated for 30 minutes at 30°C and terminated by the
addition of 5X gel loading buffer. The entire reactions were loaded onto 12% SDS-PAGE for
separation analysis and run at 100V for ~1.5 hours. The gels were stained with Coomassie blue
dye and destained in a 30% methanol and 10% glacial acetic acid solution, and subsequently
dried and exposed to Phorsphorimage® screens (Kodak). The autoradiography images were
quantified with signal intensity values using PfPK6 autophosphorylation as a 0% reference and
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PfPK6’s ability to phosphorylate the control substrate Histone as the 100% value. Signals were
normalized using these parameters.
2.1.6 Expression of Interactors Using TNT Wheat Germ Transcription and Translation Assay
Because of poor expression from pET30 EK/LIC cloning and because cell free assays
have been shown to perform better with P. falciparum’s AT rich genome, constructs of
PF11_0154, PFF0625W, and PF11_0305 were generated for expression using the TNT Wheat
Germ® overexpression assay. The genes of interest were amplified from P. falciparum cDNA
using PCR amplification. The inserts were then digested using restriction enzyme digests with
Pme1 and Sgf1 and ligated into a Flexi 3A-BYDV vector (Promega) containing a T7 promoter
region flanked by barley yellow dwarf virus for enhanced transcription in a cell-free
environment. The clones were verified using Sanger Sequencing to ensure proper ORF
orientation and base pair sequence. The correct clones were then transformed into XL10 gold
competent cells and grown up in 500mL Miller Luria Broth overnight at 37°C. The DNA was
extracted using the Qiagen Maxi Plasmid Extraction Kit® and performed according to
manufacturer instructions. To express the interactors, the Promega TnT SP6 High-Yield Wheat
Germ Expression System® kit was used and performed according to manufacturer guidelines.
3µg of DNA from each interactor was mixed with 30 µL of WheatGerm Master Mix containing
caseamino acids and the Wheat Germ complex of transcription/translation proteins, as well as
20µCi of [35S] Methionine for detection of expression, and brought to a total volume of 50µL.
The reaction was incubated for 2 hours at 25°C. An aliquot of 2µL was analyzed using SDSPAGE and run at 100V for ~1.5 hours and the rest of the samples were stored at -20°C for future
use. The gels were fixed in a solution of 50% methanol/7% acetic acid for fifteen minutes,

23

followed by a solution of 7% methanol, 7% acetic acid, 7% glycerol for ten minutes. The gel
was prepared for drying by soaking in 10% glycerol for 15 minutes, then was placed on top of
Whatman 3MM filter paper and dried for 2 hours at 80°C using a conventional gel drier. The
dried gel was exposed to a Phosphorimaging® screen (Kodak) for 48 hours to ensure the correct
expression of the interactor of interest.
2.1.7 In vitro Verification of Interaction using Interactor Specific Pull Down Assay
In order to validate the protein-protein interactions originally discovered through AntiHA Co-Immunoprecipitation analysis, pull down assays using GST-PfPK6 to pull out TNT®
generated PF11_0154, PFF0625W, and PF11_0305 were performed using the MagneGST®
protein purification kit from Promega. Interactors were analyzed both in the presence of the
kinase and with beads alone in order to eliminate non-specific binding. 20 µL of MagneGST
beads were aliquoted for each reaction and equilibrated in MagneGST Binding/Wash buffer
(neutral PBS). After equilibration, the aliquots were resuspended in 100 µL of Binding/Wash
buffer and divided into two equal volumes for the control and the kinase reactions. To prevent
non-specific binding, the beads were blocked in 1% BSA for one hour with end-over-end mixing
at 4°C. The blocking solution was removed and 200 µL of Binding/Wash buffer containing
25µg of GST-PfPK6 was added to each reaction. For control reactions, 200µL of Binding/Wash
buffer was used. The reactions were incubated for 1 hour with end-over-end mixing at 4°C. The
supernatant was removed and saved for analysis and the beads were washed three times using
250µL of Binding/Wash buffer. A 5µL aliquot of beads with kinase was taken as a measure of
binding efficiency. After the final wash, the prey was captured using 10 µL of TNT reaction for
each pull-down (control and kinase added). The prey was incubated on the beads for 6 hours
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with end-over-end mixing at 4°C. The supernatant was removed and the samples were washed 5
times with 400µL of Binding/Wash buffer. After the final wash, the samples were eluted by
addition of 20µL of 1X gel loading buffer and the beads were boiled directly to remove bound
proteins. The samples were analyzed using SDS-PAGE. One gel was stained with Coomassie
blue stain and destained overnight with a 30% methanol/10% acetic acid solution for
visualization, and the other was fixed in a solution of 50% methanol/7% acetic acid for fifteen
minutes, followed by a solution of 7% methanol, 7% acetic acid, 7% glycerol for ten minutes.
The gel was prepared for drying by soaking in 10% glycerol for 15 minutes, then was placed on
top of Whatman 3MM filter paper and dried for 2 hours at 80°C using a conventional gel drier.
The dried gel was exposed to a Phosphorimaging® screen (Kodak) for 48 hours and imaged with
quatitative analysis of the interactor alone vs. with the presence of PfPK6.
2.1.8 In vivo Verification of Interaction

In order to truly confirm that PfPK6 interacts directly with any of the putative binding
partners, the interaction needs to be verified in vivo to rule out non-specific conditions for
binding. This is in the process of being accomplished through transfection of parasites
containing epitope-tagged PfPK6 with RFP tagged interactors using a pDC vector. Currently,
only one construct has been created, but we are working to verify the other six interactors chosen
for further study.
2.1.8.1 Culturing of Malaria Parasites
Wild type DD2 cell lines of P. falciparum were initially grown in culture medium
containing RPMI 1640 supplemented with 10% Albumax II synthetic serum and A+ erythrocytes
at 4% hematocrit. The cultures were kept around 5-10% parasitemia and monitored using
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Geimsa-stained thin blood smears. Cultures were alternately split and given fresh erythrocytes to
maintain the desired parasitemia.
2.1.8.2 Cloning into pDC Vector and DNA purification
In order to transfect the potential interactors into P. falciparum parasites, the genes of
interest were cloned into a custom pDC transfection vector containing an RFP tag and selective
marker for WR 99210 resistance constructed by Marcus Lee. PFF0695W was amplified from P.
falciparum cDNA using PCR amplification. The product was digested using a restriction
enzyme digest with AvrII and BglII and subsequently ligated into a linearized vector that was
digested with the same enzymes and treated with Anartic Phosphatase to prevent self-ligation.
The potential clones were verified with Sanger sequencing to ensure correct base pair sequence
and correct reading frame orientation. The correct construct was transformed into XL 10 gold
competent cells and grown up in 500mL LB overnight at 37°C. The DNA was extracted from
the culture using the Qiagen Maxi Plasmid Purification System® according to manufacturer
guidelines.
2.1.8.3 Transfection of DNA into Live WT DD2 Parasites
Transfections were performed using pre-loaded electroporated RBCs to supplement a
5mL culture of DD2 Wild-Type parasites. 350µL of fresh RBCs in a 50% solution of serum-free
RPMI 1640 were centrifuged at 3000 rpm for 10 minutes at 4°C and supernatant was removed.
The cells were then washed in 700µL of Incomplete Cytomix containing 120 mM KCl, 0.15 mM
CaCl2, 2 mM EGTA, 5 mM MgCl2, 10 mM K2HPO4/ KH2PO4, 25 mM Hepes, (pH 7.6) and
centrifuged as before. The washed RBCs were then resuspended in 400µL Cytomix containing
100µg of purified DNA and added to a 0.2 mm electroporation cuvette (BioRad). The cells were
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then electroporated using the parameters of 31kV, 920µFD, and ∞Ω with time constants
generated between the ranges of 10-14 ms. The electroporation reaction was resuspended in
5mL of serum-free RMPI 1640 and centrifuged as before. The pellet was resuspended in 500µL
of serum-free RPMI 1640 and added to a 5mL culture of DD2 WT parasites at ~7% parasitemia.
The culture media was changed daily, and at six days drug pressure was started with a 2.5nM
solution of WR 99210 in RPMI media, which was changed daily. The cultures were monitored
using Geimsa smears and 25µL of fresh erythrocytes were added every ~5 days as needed.
2.1.8.4 Immunofluorescence Assay
In order to visualize the localization of PFF0695W, immunofluorescence assays were
performed against the RFP tag as well as against the GFP tag of a separate PfPK6-GFP tagged
cell line. 5mL of culture at ~5% parasitemia was harvested via centrifugation at 1500rpm for 3
minutes at 4°C and the supernatant was removed. The pellet was washed once with serum-free
RPMI 1640 and centrifuged as described above. The sample was then resuspended in 3mL of a
fixation solution containing 4% paraformaldehyde and 0.0075% glutaraldehyde in PBS pH 7.4
and incubated at 37°C for 30 minutes with gentle rocking. The samples were washed with 1X
PBS and centrifuged at 1850 rpm for 3 minutes, and the supernatant was removed. The pellet
was resuspended in 3mL of permeablization solution containing 0.1% of Triton X 100 in 1X
PBS pH 7.4 and incubated at 25°C for 10 minutes. The sample was then washed and centrifuged
as before. 3mL of blocking solution containing 3% BSA in neutral PBS was added and the
sample was incubated for one hour at 25°C with gentle rocking. The sample was washed and
centrifuged and 1mL of fresh blocking solution with the addition of a 1:100 dilution of Rabbit
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anti RFP antibody (transfected line) or Goat-anti-GFP (PfPK6 GFP cell line) was added and
incubated overnight at 4°C with end-over-end mixing.
The following morning, the samples were centrifuged at 2000 rpm for 3 minutes at 4°C
to remove blocking solution and were washed three times in 1X PBS. 1mL of fresh blocking
solution was added with a 1:1000 dilution of Anti-rabbit or Anti-goat secondary antibodies
conjugated to Alexa 488 fluorophore and incubated for two hours in the dark at 25°C with endover-end mixing. The samples were centrifuged and washed three times as before.
In order to prepare the coverslip for imaging, the glass was first immersed in 70% ethanol
and then allowed to air dry. Next, 300µL of poly-L-lysine was added to the coverslip and
incubated at 25°C for fifteen minutes. Excess liquid was removed and the slip was allowed to air
dry. 200µL of 1X PBS was added to the coverslip and mixed with ~8µL of the IFA reaction;
this solution was incubated for 15 minutes at 25°C. The excess liquid was removed and the slip
was dried. Finally, the slide was coated with 10µL of DAPI fluoromount and the coverslip was
placed directly on top of the DAPI, cell-side down. The IFAs were imaged using confocal
microscopy.
2.2: Results and Discussion
Characterizing and verifying the putative substrates of PfPK6 generated from
phosphoproteomics analysis as well as the interactome generated from HA-PfPK6 CoImmunoprecipitation assays has led to a better understanding of PfPK6 and its unique function in
the malarial cell cycle. The methods above have produced promising results upon which we can
build the basis of a preliminary PfPK6 interactome.
2.2.1: In Vitro Kinase Assays Reveal Two Novel Substrates of PfPK6
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Based on previous global phosphoproteomics analysis, four putative substrates were
chosen for further investigation, and used in in vitro kinase assays. The purpose of this
experiment is to show PfPK6 utilization of ATP in the presence of a putative substrate as
measured by (γ-32P) signals on a Phosphorimage® detection screen. If PfPK6 were able to
phosphorylate any of the putative substrates more than the control, histone, we would consider
this protein to be a direct substrate of PfPK6. The four putative substrates chosen for further
intestigation were MAL7P1.38, PFE0155w, PF11_0332, and PF10_0047, based on the presence
of the pS/T-P-X-K/R motif or the results of PTMScan® Direct immunoprecipitation analysis.
MAL7P1.38 was the only one of the four to be identified through both types of analysis.
The kinase assays were performed using 1µg of PfPK6 and 5µg of putative substrate in
each assay. Each substrate was also assessed alone to eliminate any substrate
autophosphorylation. Since PfPK6 demonstrates robust autophosphorylation without the
presence of any known cyclin, no Plasmodium or other eukaryotic cyclins were used in this
particular kinase assay. The assays were performed in duplicate to ensure elimination of human
error. Quantitative analysis using the parameters of PfPK6 autophosphorylation as the 0% value
and ability to phosphorylate the control histone as 100% was used to show utilization of
radiolabeled ATP.
Through this study, we were able to identify two novel substrates of PfPK6, MAL7P1.38
and PF10_0047. MAL7P1.38, which is a putative regulator of chromosome condensation,
showed a 276% increase over autophosphorylation while PF10_0047, a putative RNA binding
protein, showed significantly lower phosphorylation at 50%. Previous experiments have shown
that PfPK6 does not localize in the nucleus, however, the protein’s ability to phosphorylate a
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regulator of chromosome condensation suggest that it may function by shuttling different
proteins into/out of the nuclear envelope or activating them for their nuclear functions. Further
in vivo analysis of the confirmed substrates may be able to show co-localization events using
IFAs or FRET analysis. Figure 8 shows the results.
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Figure 8: In Vitro Kinase Assays
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(A) Coomasie blue stained gel of the in vitro kinase assays. Lane 1: Master mix, Lane 2:
Histone, Lane 3: PfPK6, Lane 4: PfPK6 + Histone, Lane 5: MAL7P1.38, Lane 6: PfPK6
+ MAL7P1.38, Lane 7: PFE0155w, Lane 8: PfPK6 + PFE0155w. (B) Coomassie blue
stained gel of the in vitro kinase assays. Lane 1: PF11_0332, Lane 2: PfPK6 +
PF11_0332, Lane 3: PF10_0047, Lane 4: PfPK6 + PF10_0047 (C) Phosphorimage of the
in vitro kinase assay gel depicted in (A)Coomassie blue stained gel of the in vitro kinase
assays (D) Phosphorimage of the in vitro kinase assay gel depicted in (B). (E)
Normalized signal intensity values. Master mix alone was set as the 0% value and PfPK6
auto-phosphorylation was set as the 100% value.
2.2.2: Recombinant Expression of Putative Interactors to Validate Interaction with PfPK6
Fifteen novel interactors were identified using Anti-Ha Co Immunoprecipitation analysis of
an HA-PfPK6 Plasmodium cell line. These fifteen interactors were scored using a ratio of their
presence in a control wild-type cell lysate eluent compared to presence in the HA-PfPK6 eluent.
The six interactors with the highest ratios were chosen for further analysis. Initially, we planned
to verify these interactions using purified His-Tagged proteins generated from a bacterial
construct. These plans included reverse pull-down assays, using a MagneHis® (Promega)
purification system to pull out purified interactors, which would in turn pull out PfPK6.
However, analysis and verification of the PfPK6 interactome posed some challenges to the study,
the first of which consisted of the failure of the recombinant proteins cloned into pET30 EK/LIC
to express in bacterial constructs under induction conditions. Different conditions including
amount of IPTG ranging from 0.1mM- 2mM, temperatures from 20°C to 37°C, and varying
growth times from 2 to 20 hours and combinations of all of the above failed to produce visible
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overexpression of any of the three putative interactors that had been cloned into the pET30
vector. Western blot analysis revealed low expression levels of PFF0625W, and PF11_0305 at
the correct size after denaturing SDS-PAGE, however, the expression was not high enough to
extract usable amounts of pure protein using affinity chromatography (See Figure 9). The genes
of interest showed correct ORF orientation and correct base pair sequence with no mutations,
and other reagents were discounted based on successful purifications of His-tagged putative
substrates. Future directions will include usage of a more robust expression vector, such as a Histagged PGEXP1 because of ample expression shown by PfPK6. Use of Rosetta cells may also
be tested to see if the discrepancy is caused by rare codons or the AT rich nature of the malaria
genome. Figure 9 shows the low levels of expression of the pET30 EK/LIC cloned interactors,
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Figure 9: Expression of pET30 Cloned Interactors

33

PF11_0305

Control
NonInduced

PFF0625w

Control
NonInduced

PF11_0154

(B)

Control
NonInduced

PF11_0305

Control
NonInduced

PFF0625w

Control
NonInduced

PF11_0154

(A)

Control
NonInduced

detectable only by Western Blotting.

(A) Coomassie blue stained gel of pET30 EK/LIC inductions. Lane 1: Marker, Lane 2: Control
non-induced culture (30°C for 12 hours), Lane 3: PF11_0154 culture induced at 1mM (30°C
for 12 hours), Lane 4: Control non-induced culture (30°C for 12 hours), Lane 5: PFF0625W
culture induced at 1mM (30°C for 12 hours), Lane 6: Control non-induced culture (30°C for
12 hours), Lane 7: PF11_0305 culture induced at 1mM (30°C for 12 hours) (B) Western Blot
of Coomassie gel in (A).
Pull Down Assays Using TNT® Wheat Germ Expressed Interactors Confirm Interaction with
PfPK6
Due to poor protein expression of the putative interactors with bacterial systems and also
due to evidence showing that Plasmodium proteins are expressed better under cell-free
conditions, constructs of putative interactors PF11_0154, PFF0625W, and PF11_0305 were
generated using Flexi 3A BYDV vectors for cell-free Transcription and Translation expression
using Wheat Germ extract. These interactors were radiolabeled with [35S] methionine for
detection and were successfully expressed using the Promega system (Figure 10.A). These were
then used in interactor-specific pull down assays against a no-kinase control to eliminate nonspecific binding with beads (Figure 10.B and 10.C). Coomassie staining of a gel containing
elution fractions confirmed PfPK6 binding to MagneGST beads and kinase absence in the
control elution. Autoradiography of the pull-downs show a clear band of the respective
interactors in the presence of the kinase, but a much lower signal in the control, suggesting the
that it is binding with PfPK6 and not the MagneGST beads that is pulling the interactors out of
solution. The ability of the kinase to pull out these interactors in their pure form suggests that
the interactions identified by the HA-Co Immunoprecipitation assays are true interactors and
34

should be subject to further study. PF11_0154 is a conserved Plasmodium protein, so little is
known about its function, and motif analysis via ProSite reveals no common motifs that may
indicate function. PFF0625W is a putative nucleolar GTP-binding protein and PF11_0305 is an
RNA methyltransferase and their nuclear location may further support the suspicion that PfPK6
shuttles nuclear proteins in and out of the nuclear envelope. These proteins may indicate a role
for PfPK6 in transcription because of multiple RNA associated substrates and interactors.
Further investigation using in vivo transfection techniques are necessary to verify the interaction
of PfPK6 and these putative interacting partners in the living cell. Figure shows the results of the
TNT® wheat germ expression and the pull down assay using these radiolabeled interactors, as
well as a quantified table showing interactor presence in the control vs. with the addition of
PfPK6.
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Figure 10: Pull Down Assays Using TNT Wheat Germ Expressed Interactors
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(A) Phosphorimage showing cell-free expression of interactors using TNT Wheat Germ
system. Lane 1: PF11_0154, Lane 2: PFF0625W, Lane 3: PF11_0305. (B) Coomassie
Blue Stained gel showing presence of PfPK6 after elution. Lane 1: Marker, Lane 2:
Kinase Only Control. Lane3: PF11_0154 Bait Flow-through, Lane 4: PF11_0154
Elution, Lane 5: PFF0625w Control (no kinase) Bait Flow-through, Lane 6: PFF0625w
Control (no kinase) Elution. Lane 7: PFF0625w Bait Flow-through, Lane 8: PFF0625W
Elution, Lane 9: PF11_0305 Control (no kinase) Bait Flow-through, Lane 10: PF11_0305
Control (no kinase) elution, Lane 11: PF11_0305 Bait Flow-through, Lane 12:
PF11_0305 Elution (C) Phosphorimage of pull down assay showing radiolabeled
interactor elution. Lane 1: Pf11_0154 alone, Lane 2: PF11_0154 +PfPK6, Lane 3:
PFF0625w alone, Lane 4: PFF0625w +PfPK6, Lane 5: PF11_0305 alone, PF11_0305 +
PfPK6 (D) Graph showing interactor signal intensity of control interactor alone and with
PfPK6 to quantify and eliminate non-specific binding normalized with background
readings at 0%
2.2.4 In vivo Analysis of Interactor Localization will Lead to Future Verification of PfPK6
Interaction within the Parasite
Understanding the binary interactions of PfPK6 and the putative binding partners in vitro
is an important step to defining a PfPK6 interactome. However, proteins in any given
environment may not behave the same as they do in the living organism, as so many various
factors are missing from the experimental environment. In order to further confirm the
interactions, we planned to transfect RFP-tagged forms of the six interactors into parasites
containing tagged forms of PfPK6. Transfection of the parasites with PFF0695w gave us the
opportunity to study the localization of the putative binding partner in vivo using
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immunofluorescence assays (Figure 11). This interactor shows a very interesting pattern of
localization: in the early stages of the parasite, including ring and early trophozoite, the protein is
located only within the parasite and is extranuclear. However, during later stages of
development, the protein can be seen throughout the human red blood cell. This suggests that
PFF_0695w may be a part of the malaria secretome and may be exported via vesicles into the
host cell, which would have exciting implications for PfPK6 as a binding partner. Phyre analysis
was used to generate a putative structure for the interactor, and the helical nature and presence of
an 18% identity c3jb9i motif homologous to the yeast splicosome suggest that this protein is an
RNA binding protein involved in mRNA splicing. Although this peptide is not in the known
secretome [27], and the PEXEL motif is absent, this does not eliminate the possibility that this
protein is secreted into the RBC. PfEMP, a known secreted peptide and a widely studied
Plasmodium derived RBC surface protein, does not contain a PEXEL motif and is yet secreted
by the organism into the host. The malaria genome is unique in its composition, and it may be
the case that the PEXEL motif is replaced by structurally similar amino acids, such as in PfPK6
where PSTAIRE is changed to SKCILRE. Further analysis is required to confirm these findings,
including the transfection of PFF_0695w into a GFP-tagged cell line of P. falciparum to assess
their ability to co-localize, as well as further investigation into the function of PFF0695w.
Future initiatives include the cloning of the remaining five interactors into pDC vectors for
transfection into GFP-PfPK6 cell lines of Plasmodium falciparum. Figure 11 shows the
localization of PFF_0695w in the cell at the different stages of development, as well as the
general localization of PfPK6 (perinuclear) (Figure 11).
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Figure 11: Immunofluorescence Assay of PFF0695w and PfPK6

(A)Immunofluorescence assay using Rabbit-Anti- RFP primary antibody and Goat-AntiRabbit conjugated to Alexa 488 fluorophore showing localization of PFF0695W.
(B)Immunofluorescence assay using Mouse-Anti-GFP primary antibody and Goat-AntiMouse conjugated to Alexa 488 fluorophore showing localization of PfPK6
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2.3 Conclusions

In summary, PfPK6 is a unique kinase in Plasmodium falciparum that is essential to the cell,
as shown by functional knockout studies resulting in parasite death [24]. As a CDK-like and
MAPK- like kinase, it may be function in the regulation of the non-canonical cell cycle of
growth, proliferation, and differentiation. Although PfPK6 shows structural similarity to CDKs,
there is evidence that it may act as a cyclin-independent kinase, as it does not require stimulation
by any known cyclin in order to activate auto-phosphorylation. Understanding the biochemical
interaction network of this atypical kinase is essential to understanding its function in the cell
cycle as well as demonstrating use as a potential therapeutic target by using a binding surface or
upstream regulator as a target rather than an ATP-binding pocket inhibitor. We have
demonstrated PfPK6’s ability to phosphorylate MAL7P1.38 and PF10_0047, a regulator of
chromosome condensation and an RNA binding protein. These novel substrates suggest PfPK6
may play a role in transcription or translation of various genes, even though it maintains an
extranuclear location. We have verified three non-substrate interactors PF11_0154, PFF0625W,
PF11_0305, via pull-down analysis with GST-PfPK6 and TNT® wheat germ expressed versions
of the interactors. Clear presence of the interactor with the presence of kinase compared to its
absence without kinase confirms the binary interaction outside of the cell. Immunofluorescence
assays of the transfected lines containing RFP-tagged PFF0695w showed a punctate extracellular
location in the later stages of the intraerythrocytic cell cycle, suggesting this is a novel protein in
the Plasmodium falciparum secretome. Future work will consist of generating pDC constructs
of the other five interactors and transfecting into GFP- tagged PfPK6 cell lines to determine colocalization and interaction in vivo. Further characterization of substrates and interactor
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functions will provide a clearer understanding of PfPK6’s function in the malarial cell cycle.
The information in this study has allowed us to generate a preliminary interaction network for
PfPK6. This is based on the interactors confirmed in this study as well as yeast-two-hybrid
peptide interactors of our interactors shown in other studies. This preliminary interactome may
not yet be complete, but it is the first step in defining an interactome for PfPK6, an atypical
CDK-like kinase. Figure 12 shows the preliminary PfPK6 Interaction network.
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Figure 12: Preliminary Interaction Networks of PfPK6
Preliminary interactome of PfPK6 based on substrates and interactors in this study. Green: Interactors identified by
HA Co-Immunoprecipitation and verified using in vitro pull down assays. Purple: Interactors identified by HA CoImmunoprecipitation and not yet confirmed. Pink: Identified by HA Co-Immunoprecipitation and currently being
verified using in vivo techniques. Yellow: Direct substrates identified in this study. Orange: Previously identified
substrates. Red: Interacting peptides identified by previous yeast-two hybrid studies.ss
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